Systemic agents for focal symptoms: A promising pasture or a potential snare?

Menopause

Volumn 21, Issue 3, 2014, Pages 213-

  Pal, Lubna ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; OSPEMIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG SAFETY; EDITORIAL; ESTROGEN THERAPY; HORMONAL THERAPY; HUMAN; MENOPAUSAL SYNDROME; TARGET ORGAN; UNITED STATES; VAGINA ATROPHY; VENOUS THROMBOEMBOLISM;

FEMALE; HUMANS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; VAGINA; VULVA;

EID: 84896716953     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000205     Document Type: Editorial

References (7)

1. Stuenkel CA, Gass ML, Manson JE, et al. A decade after the Women's Health InitiativeVthe experts do agree. Menopause 2012;19:846-847.
2. Fischer C, Kallen AN, Pal L. Hormone therapy: A to Z. Menopause 2013; 20:1204-1206.
3. FDA approves Osphena for postmenopausal women experiencing pain during sex. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm341128.htm. Accessed January 19, 2014.
4. Pinkerton JV, Stanczyk FZ. Clinical effects of selective estrogen receptor modulators in vulvar and vaginal atrophy. Menopause 2014;21:309-319.
5. Artero A, Tarín JJ, Cano A. The adverse effects of estrogen and selective estrogen receptor modulators on hemostasis and thrombosis. Semin Thromb Hemost 2012;38:797-807.
6. The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888-902.
7. WHI HT updateV2002. Available at: http://www.nhlbi.nih.gov/health/women/ upd2002.htm. Accessed January 19, 2014.